Insider · CIK 0001652023

Reverberi Gian Piero

Reports to the SEC for 1 company · WASHINGTON, DC

sec.gov

Transactions

Companies

Filings

CIK

0001652023

Forms 4 and 5

Insider transactions

24 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2020-03-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−1,450 sh	$10.18	−$14.8K	165,384
2020-01-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−1,155 sh	$16.06	−$18.6K	166,834
2019-03-04	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−443 sh	$19.92	−$8,822.788	167,989
2019-03-01	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−438 sh	$20.16	−$8,832.27	168,432
2019-02-27	VNDAVanda Pharmaceuticals Inc.A Award	SVP & Chief Commercial Officer	AAward	+30K sh	—	—	168,870
2019-02-27	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP & Chief Commercial Officer	AAward	+70K sh	—	—	70,000
2019-01-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−600 sh	$26.28	−$15.8K	139,400
2019-01-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP & Chief Commercial Officer	SSale	−530 sh	$26.93	−$14.3K	138,870
2018-02-28	VNDAVanda Pharmaceuticals Inc.A Award	SVP & Chief Commercial Officer	AAward	+30K sh	—	—	140,000
2018-02-28	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP & Chief Commercial Officer	AAward	+70K sh	—	—	70,000
2018-01-02	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+12.5K sh	—	—	87,500
2018-01-02	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+7,500 sh	—	—	110,000
2018-01-02	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitM Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	−12.5K sh	—	—	25,000
2018-01-02	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitM Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	−7,500 sh	—	—	15,000
2017-03-01	VNDAVanda Pharmaceuticals Inc.A Award	SVP & Chief Commercial Officer	AAward	+30K sh	—	—	50,000
2017-03-01	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP & Chief Commercial Officer	AAward	+70K sh	—	—	70,000
2017-01-03	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+12.5K sh	—	—	12,500
2017-01-03	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+7,500 sh	—	—	20,000
2017-01-03	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitM Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+12.5K sh	—	—	37,500
2017-01-03	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitM Exercise/Conversion	SVP & Chief Commercial Officer	MExercise/Conversion	+7,500 sh	—	—	22,500
2016-02-12	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP & Chief Commercial Officer	AAward	+70K sh	—	—	70,000
2016-02-12	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitA Award	SVP & Chief Commercial Officer	AAward	+30K sh	—	—	30,000
2015-09-08	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP & Chief Commercial Officer	AAward	+150K sh	—	—	150,000
2015-09-08	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitA Award	SVP & Chief Commercial Officer	AAward	+50K sh	—	—	50,000

Recent filings

Accepted (ET)
Mar 44
Reverberi Gian Piero0001209191-20-016208
SEC(opens sec.gov)
Jan 64
Reverberi Gian Piero0001209191-20-002032
SEC(opens sec.gov)
Mar 44
Reverberi Gian Piero0001209191-19-015749
SEC(opens sec.gov)
Mar 14
Reverberi Gian Piero0001209191-19-014980
SEC(opens sec.gov)
Jan 44
Reverberi Gian Piero0001209191-19-002004
SEC(opens sec.gov)
Mar 24
Reverberi Gian Piero0001209191-18-015891
SEC(opens sec.gov)
Jan 44
Reverberi Gian Piero0001209191-18-002067
SEC(opens sec.gov)
Mar 34
Vanda Pharmaceuticals Inc.0001209191-17-017811
SEC(opens sec.gov)
Jan 54
Vanda Pharmaceuticals Inc.0001209191-17-002211
SEC(opens sec.gov)

Companies

Vanda Pharmaceuticals Inc.SVP & Chief Commercial OfficerVNDA

Address

2200 PENNSYLVANIA AVENUE SUITE 300E

WASHINGTON, DC, 20037